In Trodelvy pact, Gilead drawing clinical expertise from Abingworth’s Launch team

As Gilead navigates a challenging clinical path to extract further value out of Trodelvy via label expansions, the biopharma has struck a deal with Abingworth to support at least one late-stage study of the ADC while drawing on the clinical expertise of the firm’s Launch entity.

The deal is the latest late-stage clinical agreement for Abingworth, which has a long history of risk-sharing deals with both large pharmas and small biotechs. Since 2009, the firm has serially entered bespoke pacts in which it helps fund pivotal studies in exchange for a return if the product gains approval or reaches other milestones...